EUVIMEDEUVIMED entdecken
Crossref

Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe

Lalawmpuii Pachuau, H Lalremmawia, Lalengkimi Ralte, Johan Vanlalpeka, Jeremy Lalrinsanga Pautu, Saia Chenkual, Thomas Zomuana, Sailo Tlau Lalruatfela, John Zohmingthanga, Lalchhandama Chhakchhuak, Ashok K Varma, Nachimuthu Senthil Kumar

Breast Cancer Research and Treatment · 2025

DOI: 10.1007/s10549-024-07501-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von Lalawmpuii Pachuau und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Mizoram University, Tanhril, Aizawl, Mizoram, 796004, India. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Mutation, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The incidence of triple-negative breast cancer (TNBC) in India is higher compared to Western populations. The objective of this study is to identify novel and less reported variants in TNBC in Mizoram, a state with a high cancer incidence in India. METHODS: We analysed whole exome sequencing data from triple-negative breast cancer (TNBC) patients in the Mizo population to identify key and novel variants. Moreover, we analysed reported breast cancer-related genes and pathway alterations. RESULTS: Somatic mutation analysis revealed that TP53 was the most frequently mutated gene and TP53, CACNA1E, IGSF3, RYR1, and FAM155A as significantly mutated driver genes. Based on the ACMG guidelines, we identified a rare pathogenic germline variant of BRCA1 (p.C1697R) in 13% and a likely pathogenic frameshift insertion in RBMX (p.P106Ffs) in 73% of the patients. We also found that the ATM, STK11, and CDKN2A genes were significantly mutated in germline TNBC samples compared to healthy samples. Moreover, we identified novel somatic variants in CHEK2 (p.K182M) and NF1 (p.C245X), and novel germline variants RB1 (p.D111G), CDH1 (p.A10Gfs), CDKN2A (p.V96G), CDKN2A (p.S12Afs*22), MAP3K1 (CAAdelins0), MSH6 (p.L1226_L1230del), and PMS2 (TTCdelins0). Pathway analysis revealed that most somatic mutations were highly associated with PI3K-Akt signalling pathway and MAPK signalling pathways in TNBC. CONCLUSIONS: These findings identified novel variants and key genes contributing to disease development and progression. Further analysis of less studied genes, including RBMX, MRC1, ATM, CTNNB1, and CDKN2A, in TNBC may reveal new potential genes for targeted therapeutic strategies and contribute to clinical advancements in the treatment of TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsMutationBiomarkers, TumorHumansFemaleIndiaExome SequencingMiddle AgedAdultGerm-Line MutationGenetic Predisposition to DiseaseSignal TransductionAged

Stichwörter der Autor:innen

Mutational signaturePathogenic variantSomatic and germline variantsTriple-negative breast cancerWhole-exome sequencing

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biotechnology, Mizoram University, Tanhril, Aizawl, Mizoram, 796004, India.
  • Department of Pathology, Department of Health & Family Welfare, Civil Hospital Aizawl, Government of Mizoram, Dawrpui, Aizawl, Mizoram, 796001, India.
  • Department of Medicine, Zoram Medical College, Falkawn, Aizawl, Mizoram, 796 005, India.
  • Department of Medical Oncology, Mizoram State Cancer Institute, Zemabawk, Aizawl, Mizoram, 796017, India.
  • Department of Surgery, Department of Health & Family Welfare, Civil Hospital Aizawl, Government of Mizoram, Dawrpui, Aizawl, 796001, Mizoram, India.
  • Zoram Medical College, Falkawn, Aizawl, Mizoram, 796 005, India.

Zitieren

APA

Pachuau, L., Lalremmawia, H., Ralte, L., Vanlalpeka, J., Pautu, J. L., Chenkual, S., Zomuana, T., Lalruatfela, S. T., Zohmingthanga, J., Chhakchhuak, L., Varma, A. K., & Kumar, N. S. (2025). Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07501-9

Vancouver

Pachuau L, Lalremmawia H, Ralte L, Vanlalpeka J, Pautu JL, Chenkual S, et al. Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-024-07501-9

BibTeX
@article{Pachuau2025,
  author = {Pachuau, Lalawmpuii and Lalremmawia, H and Ralte, Lalengkimi and Vanlalpeka, Johan and Pautu, Jeremy Lalrinsanga and Chenkual, Saia and Zomuana, Thomas and Lalruatfela, Sailo Tlau and Zohmingthanga, John and Chhakchhuak, Lalchhandama and Varma, Ashok K and Kumar, Nachimuthu Senthil},
  title = {Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  doi = {10.1007/s10549-024-07501-9}
}
Kostenlos starten →